Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Michael Wiessner has worked on the following 22 EPO patent applications which have been published in the last five years:

EP12700701

4-TOLYL-ETHYNYL-OCTAHYDRO-INDOLE-1-ESTER DERIVATIVES

IPC classification:
A61K 31/403, A61P 25/00, C07D 209/26
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12700262

IMMUNOSUPPRESSANT FORMULATIONS

IPC classification:
A61K 9/20, A61K 31/397
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP11757513

USE OF 1H-QUINAZOLINE- 2, 4 -DIONES FOR USE IN THE PREVENTION OR TREATMENT PHOTOSENSITIVE EPILEPSY

IPC classification:
A61K 31/517, A61P 25/08, C07D 239/96, C07D 403/04, C07D 405/04
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12772986

DOSAGE REGIMEN FOR AN S1P RECEPTOR MODULATOR OR AGONIST

IPC classification:
A61K 31/132, A61K 31/137, A61K 31/196, A61K 31/397, A61P 37/00
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12701342

USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS

IPC classification:
A61K 31/00, A61P 25/16
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13702472

PROCESS FOR PREPARING N-(4-CYCLOHEXYL-3-TRIFLUOROMETHYL-BENZYLOXY)-ACETIMIDIC ACID ETHYL ESTER

IPC classification:
C07C 22/08, C07C 33/34, C07C 47/55, C07C 251/48, C07D 205/04
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13173514

Immunosuppressant Compounds and Compositions

IPC classification:
A61K 31/4725, A61P 35/00, C07D 261/20, C07D 333/58, C07D 409/06, C07D 471/04, C07D 473/00, C07D 513/04
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11802917

4- (HETERO) ARYL - ETHYNYL - OCTAHYDRO - INDOLE - 1 - CARBOXYLIC ACID ESTERS

IPC classification:
A61K 31/404, A61K 31/427, A61K 31/4439, A61P 1/00, A61P 13/02, A61P 25/00, C07D 209/08, C07D 401/06, C07D 417/06
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11729624

CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS

IPC classification:
A61K 31/444, C07D 407/04, C07D 407/14, C07D 417/14, C07D 491/04
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11719840

2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES

IPC classification:
A61K 31/517, A61P 25/08, C07D 403/04, C07D 405/04
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP15173766

COMPOSITIONS COMPRISING SPHINGOSINE I PHOSPHATE (SIP) RECEPTOR MODULATORS

IPC classification:
A61K 9/00, A61K 9/20, A61K 9/70, A61K 31/137
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15177166

S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS

IPC classification:
A61K 31/137, A61K 31/397, A61P 37/06
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15177158

PAEDIATRIC COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS

IPC classification:
A61K 31/137, A61P 37/00
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15185231

AMINOALKANOL DERIVATIVES

IPC classification:
A61K 31/135, A61P 37/00, C07C 215/28, C07C 233/22
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15186346

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

IPC classification:
A61K 31/137, A61P 11/06, A61P 37/06, G06F 19/00
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15188591

DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR

IPC classification:
A61K 31/137, A61P 11/06, A61P 37/06, G06F 19/00
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP13154157

Pim kinase inhibitors and methods of their use

IPC classification:
A61K 31/4439, A61P 35/00, C07D 417/14
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13177190

HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3 -TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID FOR USE IN THE TREATMENT OF LYMPHOCYTE MEDIATED DISEASES

IPC classification:
A61K 31/397, A61P 35/00, A61P 37/00, C07D 205/04
Applicant:
Novartis AG
Agent:
Ter Meer Steinmeister & Partner PartGmbB
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
PATENT GRANTED
EP15735733

IMMUNOSUPPRESSANT FORMULATION

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/28, A61K 31/397
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15717256

S1P MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN

IPC classification:
A61K 9/20, A61K 31/397
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16176665

FORMULATIONS COMPRISING 2-AMINO-2-[2-(4-OCTYLPHENYL)ETHYL]PROPANE-1,3-DIOL

IPC classification:
A61K 9/16, A61K 9/20, A61K 9/48, A61K 31/137, A61K 31/661, A61K 47/40, A61P 37/06
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis Pharma AG
Status:
Request for examination was made
EP15784974

COMBINATIONS COMPRISING SIPONIMOD AND LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS

IPC classification:
A61K 31/397, A61K 31/4704, A61P 37/00
Applicant:
Novartis AG
Agent:
Michael Wiessner, Novartis AG
Status:
Request for examination was made

Please Sign in to use this feature